Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Modified FOLFOX with or without nivolumab and ipilimumab versus FLOT plus nivolumab in untreated advanced gastric or gastroesophageal junction adenocarcinoma
2017-002080-18Phase 2Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Jan 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nivolumab, ipilimumab, oxaliplatin, fluorouracil, folinic acid and 1 more in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (4 arms), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: Progression-free survival. Started Jan 2018; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2017-002080-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002080-18.